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Changes in Serum Testosterone after
Bilateral Orchiectomy in Patients with
Metastatic Carcinoma of the Prostate
Richard Senn, M D * , Riad Farah, M D * * , Julius O h o r o d n i k , M D * * * & Joseph C. C e r n y , M D *

H o r m o n a l treatment of patients with metastatic prostatic carcinoma has been directed
at lowering androgen production by the
testes. Generally, this decrease in androgen
production has been assessed by measurement of total urinary 17-keto steroid and/or
individual urinary androgen metabolites.
Recent studies indicate that such determinations are of limited value since the steroids
measured are derived from both adrenal and
gonadal precursors, some of w h i c h are
weakly androgenic, or even nonandrogenic.

From a study of 38 patients. It may be
concluded that, first, changes In serum testosterone levels of patients undergoing orchiectomy for metastatic carcinoma of the
prostate are unrelated to the clinical course
of the patient; second, no clear correlation
exists between quantitative
Leydig cell
counts and levels of plasma testosterone;
and, third, exacerbation of metastatic disease is observed while plasma testosterone
remains in the castrate range. These observations question the exact function of the
Leydig cell and Its role In androgen production, and indicate that prostatic neoplasms
have varying degrees of response to reduced
androgen levels and/or androgen-IIke substances following castration.

Plasma testosterone measurement offers a
more direct approach to the study of tumor
androgen relationships since it is the most
potent androgen secreted. Seventy percent
of testosterone measured in plasma in men
arises from the testes. The present study was
designed to evaluate the r e l a t i o n s h i p of
plasma testosterone levels to the clinical
response of patients undergoing bilateral
orchiectomy for metastatic carcinoma of the
prostate.

Materials and methods
Thirty-eight men with proven carcinoma
of the prostate and symptomatic bony metastases were treated with bilateral therapeutic
orchiectomy. Immediate preoperative and
three-day postoperative serum testosterone
levels were determined. Correlations were
made between a) preoperative testosterone
levels, b) fall in postoperative testosterone
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levels, c) acid and alkaline phosphatase, d)
testicular-Leydig cell counts, and e) presenceorabsence and length of clinical symptomatic improvement.

No significant correlation was observed
between (a) preoperative testosterone levels
and Leydig cell counts, (b) ratio of postoperative/ preoperative testosterone and degree and duration of remission of symptoms,
(c) ratio of postoperative/preoperative acid
phosphatase and degree of duration of remission of symptoms, or (d) clinical response
in patients having w e l l differentiated vs
poorly differentiated adenocarcinoma of the
prostate.

Quantitative Leydig cell determinations
were made by countingthe actual number of
Leydig cells and seminiferous tubules in 100
random fields of each testis, then averaging
the number of Leydig cells per seminiferous
tubule.
The method of plasma testosterone determination is that modified from Kato and
Hortens, u t i l i z i n g c o m p e t i t i v e protein
binding.

Clinical exacerbation of metastases following initial remission, manifested by recurrent pain, progressive osseous involvement and increasing levels of acid phosphatase activity, was not accompanied by
increase in plasma testosterone, which remained in the castrate range.

Results
Plasma testosterone, measured m u g / 1 0 0 /
ml plasma, ranged from 110 to 1404 (mean
506), prior to orchiectomy, and fell from 12
to 187 (mean 64), postoperatively. The average postoperative testosterone determination was 15% of its preoperative level.

Discussion and Conclusion
It was distressing to observe that while 36
of 38 patients had excellent immediate relief
of metastatic pain followingorchiectomy, all
but four noted varyingdegrees of recurrence
within six months postoperatively. While
prompt decrease in plasma testosterone followed orchiectomy, that decrease was neither related to Leydig cell counts or degree
and duration of remission of symptoms. Of
further interest was the observation that
plasma testosterone remained in the castrate
range in the face of recurrent activity of the
neoplasm, and response to orchiectomy was
unrelated to tumor grade.

Plasma acid phosphatase, measured in
King-Armstrong units, ranged from 4 to 317
(mean 39), prior to orchiectomy, and fell to
from 2 to 54 (mean 10), postoperatively. The
average postoperative acid phosphatase was
25% of its preoperative level.
Leydig cell counts, eg, number of Leydig
cells per seminiferous tubule, showed gradual reduction with increasing patient age.
Average numberof Leydigcells was seven in
the age group 30-39, and decreased to three
in the age group 65-75.

The poor response to orchiectomy seen in
many patients may represent a) a marginal
and transient tumor androgen dependence,
b) hypersensitivity to minute amounts of
adrenal a n d r o g e n , eg, androstanedione
which is convertible to testosterone, or c)
n o n a n d r o g e n i c factors s t i m u l a t i n g the
neoplasm.

Thirty-six of 38 patients undergoing orchiectomy noted immediate relief of osseous
p a i n . W i t h i n six months of o p e r a t i o n ,
however, 32 of the 36 noted recurrence of
varying degrees of pain, as well as other
stigmata of metastatic disease.
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